fbpx

DISCOVERY PARK NEWSLETTER – WINTER 2020 22 December, 2020

Welcome to Discovery Park’s newsletter for winter 2020.

Season’s Greetings to you all, and best wishes for a happy and healthy 2021. This year has brought us all many challenges, but hopefully the New Year will bring renewed optimism and some more certainty.

In the final few months of the year, there have been exciting developments for many of our tenants and for Discovery Park. Pfizer and its partner BioNTech have of course been in the news with the approval and roll-out of their COVID-19 vaccine. We share our Pfizer colleagues’ pride and excitement in this development.

Pfizer has been having an impact locally as well as globally. A report published in November, ‘The impact of Pfizer’s Sandwich site in the UK’, highlights its £1.2bn UK R&D spend since 2014 (primarily in Sandwich), plus other measures of its contribution. There’s more information in our response to the report below.

In other news, growing neuroscience contract research organisation Transpharmation has joined our innovative community, an exciting development for us and occupiers. You can read more about this and developments at tenants Avvinity, Reneo and Viatris (formerly Mylan) below.

Do get in touch if you have any comments, or would like to know more about our facilities, particularly our new Incubator R&D facility which we expect to open in September next year. Opening of this exciting
space for life sciences SMEs
is possible with the support of the Government’s Getting Building Fund via the South East Local Enterprise Partnership, for which we are very grateful.

We’ve enjoyed seeing you digitally at conferences such as Genesis and Bio Integrates in recent months, and hope we can welcome you to Discovery Park in person some time in 2021.

Best wishes again for a Happy New Year.

Mayer Schreiber, CEO

Dr Martino Picardo, Chairman

DISCOVERY PARK CONGRATULATES PFIZER SANDWICH ON NEW REPORT OF ITS ECONOMIC IMPACT

Congratulations to Pfizer Sandwich on its substantial economic impact in the region and across the UK, as highlighted in the new impact report. Factors such as investment in skills via schemes such as apprenticeships, and the highly trained workforce (many of whom moved to the area to work for Pfizer), are also mentioned. Read more on our response here and watch Pfizer’s video here.

NEUROSCIENCE-FOCUSED CRO TRANSPHARMATION OPENING NEW FACILITY AT DISCOVERY PARK

Contract research organisation Transpharmation is expanding, making Discovery Park its largest laboratory, and we are delighted to welcome it as a new tenant. The company, which is focused on neuroscience research, has over 100 clients worldwide and you can read more about its plans here.